Geron Corporation – NASDAQ:GERN
Geron stock price today
$1.43
-1.92
-57.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Geron stock price monthly change
-28.88%
month
Geron stock price quarterly change
-28.88%
quarter
Geron stock price yearly change
+53.67%
year
Geron key metrics
Market Cap | 2.05B |
Enterprise value | 743.34M |
P/E | -5.29 |
EV/Sales | 1507.79 |
EV/EBITDA | -3.93 |
Price/Sales | 1552.48 |
Price/Book | 9.56 |
PEG ratio | 0.92 |
EPS | -0.34 |
Revenue | 520K |
EBITDA | -204.46M |
Income | -201.39M |
Revenue Q/Q | 1347.61% |
Revenue Y/Y | 5.26% |
Profit margin | -40591.48% |
Oper. margin | -39594.52% |
Gross margin | 0% |
EBIT margin | -39594.52% |
EBITDA margin | -39320.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGeron stock price history
Geron stock forecast
Geron financial statements
Average Price Target
$6.83
Potential upside: 377.85%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 29K | -49.22M | -169748.28% |
|---|---|---|---|
| Sep 2023 | 164K | -44.80M | -27320.12% |
| Dec 2023 | 23K | -51.97M | -225973.91% |
| Mar 2024 | 304K | -55.39M | -18220.39% |
| Jun 2023 | 415296000 | 116.86M | 28.14% |
|---|---|---|---|
| Sep 2023 | 413017000 | 122.40M | 29.64% |
| Dec 2023 | 394076000 | 146.12M | 37.08% |
| Mar 2024 | 482074000 | 137.20M | 28.46% |
| Jun 2023 | -29.60M | -44.44M | 18.34M |
|---|---|---|---|
| Sep 2023 | -50.83M | -4.71M | 29.35M |
| Dec 2023 | -40.29M | 47.56M | 32.64M |
| Mar 2024 | -62.25M | 34.20M | 147.79M |
Geron alternative data
| Sep 2023 | 107 |
|---|---|
| Oct 2023 | 107 |
| Nov 2023 | 107 |
| Dec 2023 | 107 |
| Jan 2024 | 107 |
| Feb 2024 | 107 |
| Mar 2024 | 141 |
| Apr 2024 | 141 |
| May 2024 | 141 |
| Jun 2024 | 141 |
| Jul 2024 | 141 |
Geron other data
31.18%
-20.37%
of GERN is owned by hedge funds
126
-55
118.71M
-90.16M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 13186 | 0 |
| May 2024 | 0 | 35000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LAWLIS V BRYAN director | Stock Option (right to buy) | 35,000 | $1.94 | $67,900 | ||
Option | LAWLIS V BRYAN director | Common Stock | 35,000 | $1.94 | $67,900 | ||
Sale | LAWLIS V BRYAN director | Common Stock | 35,000 | $3.75 | $131,250 | ||
Purchase | O'FARRELL ELIZABETH G. director | Common Stock | 6,579 | $2.28 | $15,000 | ||
Purchase | O'FARRELL ELIZABETH G. director | Common Stock | 6,607 | $2.28 | $15,064 | ||
Option | LAWLIS V BRYAN director | Common Stock | 35,000 | $1.1 | $38,500 | ||
Sale | LAWLIS V BRYAN director | Common Stock | 35,000 | $3 | $105,000 | ||
Option | LAWLIS V BRYAN director | Stock Options (right to buy) | 35,000 | $1.1 | $38,500 | ||
Option | MOLINEAUX SUSAN director | Common Stock | 35,000 | $1.1 | $38,500 | ||
Sale | MOLINEAUX SUSAN director | Common Stock | 35,000 | $2.48 | $86,800 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Conservative Vision Of A Positive Future For Geron
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
3 'Buy-Rated' Biotech Stocks Under $10
Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case
Geron Corporation Stock: Another Buying Opportunity
Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs
-
What's the price of Geron stock today?
One share of Geron stock can currently be purchased for approximately $1.43.
-
When is Geron's next earnings date?
Unfortunately, Geron's (GERN) next earnings date is currently unknown.
-
Does Geron pay dividends?
No, Geron does not pay dividends.
-
How much money does Geron make?
Geron has a market capitalization of 2.05B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.23% to 237K US dollars.
-
What is Geron's stock symbol?
Geron Corporation is traded on the NASDAQ under the ticker symbol "GERN".
-
What is Geron's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Geron?
Shares of Geron can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Geron's key executives?
Geron's management team includes the following people:
- Dr. John A. Scarlett Chief Executive Officer, Pres & Chairman(age: 74, pay: $1,390,000)
- Dr. Aleksandra Rizo M.D., Ph.D. Executive Vice President & Chief Medical Officer(age: 50, pay: $892,290)
- Dr. Andrew J. Grethlein Executive Vice President & Chief Operating Officer(age: 61, pay: $791,520)
- Ms. Melissa A. Kelly Behrs Executive Vice President of Bus. Operations & Chief Alliance Officer(age: 61, pay: $764,810)
- Ms. Olivia Kyusuk Bloom Executive Vice President of Fin., Chief Financial Officer & Treasurer(age: 56, pay: $761,540)
-
How many employees does Geron have?
As Jul 2024, Geron employs 141 workers.
-
When Geron went public?
Geron Corporation is publicly traded company for more then 29 years since IPO on 31 Jul 1996.
-
What is Geron's official website?
The official website for Geron is geron.com.
-
Where are Geron's headquarters?
Geron is headquartered at 919 East Hillsdale Boulevard, Foster City, CA.
-
How can i contact Geron?
Geron's mailing address is 919 East Hillsdale Boulevard, Foster City, CA and company can be reached via phone at +65 04737700.
-
What is Geron stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Geron in the last 12 months, the avarage price target is $6.83. The average price target represents a 377.85% change from the last price of $1.43.
Geron company profile:
Geron Corporation
geron.comExchange:
NASDAQ
Full time employees:
141
Industry:
Biotechnology
Sector:
Healthcare
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
919 East Hillsdale Boulevard
Foster City, CA 94404
Foster City, CA 94404
CIK: 0000886744
ISIN: US3741631036
CUSIP: 374163103
